Sign in
4

Changes in Ownership

Oncotelic Therapeutics, Inc. Filed Acc 0001209191-15-061705

Options or other derivatives

  • Chief Financial Officer acquired 150,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
LOAR MATTHEW M Chief Financial Officer 2015-07-20 Grant or award · Employee Stock Option (Right to Buy) +150,000 150,000 D: show line 1 in the form
Loading xslF345X03/doc4.xml…